双抑制Wnt抑制剂DKK1与硬骨素促进骨折愈合并增加未损伤骨的密度和强度:非人灵长类实验研究
该研究在食蟹猴尺骨截骨模型中,评估16周皮下给予载体溶液、抗硬骨素抗体、抗DKK1抗体或两者联合治疗对骨折愈合及全身骨量的影响。结果显示联合治疗同时具备抗DKK1促进骨折部位骨密度和强度的作用与抗硬骨素促进全身骨形成的作用,部分效应优于单药治疗。作者认为联合抗体治疗可能为骨折治疗和预防提供有前景的策略。
要点
- 抗DKK1抗体增加尺骨截骨部位骨密度和强度,抗硬骨素抗体增加未损伤骨骼部位骨形成和骨密度。
- 联合治疗同时诱导上述所有效应,部分效应优于一种或两种单药治疗。
- 非人灵长类结果提示DKK1优先调控骨折愈合,硬骨素优先调控全身骨量。
核心结论
- 抗DKK1抗体增加尺骨截骨部位的骨密度和强度,抗硬骨素抗体增加未损伤骨骼部位的骨形成和骨密度。
- 抗硬骨素抗体联合抗DKK1抗体诱导上述所有效应,部分效应优于一种或两种单药治疗。
- 非人灵长类结果提示DKK1优先调控骨折愈合,而硬骨素优先调控全身骨量。
- 作者认为针对硬骨素和DKK1的联合抗体治疗可能为骨折治疗和骨折预防提供有前景的治疗策略。
研究设计与样本
- 研究评估16周皮下给予载体溶液、抗硬骨素抗体、抗DKK1抗体或抗硬骨素抗体联合抗DKK1抗体对非人灵长类(食蟹猴)尺骨截骨愈合的影响,每组20至22只。
主要发现
- 抗硬骨素抗体组和联合治疗组较载体组增加全身骨形成标志物,联合治疗较抗硬骨素抗体或抗DKK1抗体单药治疗产生协同增加。
- 联合治疗组和抗硬骨素抗体组较载体组降低血清骨吸收标志物。
- 联合治疗组和抗DKK1抗体组较载体组显示更大的骨痂骨密度、扭转刚度和扭转刚度。
- 抗硬骨素抗体组和联合治疗组的腰椎较载体组显示更大的骨密度和骨形成率,股骨中段骨干较载体组显示更大的骨膜和骨内膜骨形成率。
临床怎么用
- 原文结论认为针对硬骨素和DKK1的联合抗体治疗可能为骨折治疗和骨折预防提供有前景的治疗策略,但未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fracture repair involves the reactivation of developmental signaling cascades, including Wnt signaling that stimulates bone formation and bone regeneration. Rodent data indicate that dual inhibition of the Wnt signaling antagonists sclerostin and Dickkopf-1 (DKK1) increases callus bone volume and strength while increasing bone mass systemically. METHODS: We evaluated the effects of 16 weeks of subcutaneously administered carrier solution (vehicle, VEH), anti-sclerostin antibody (Scl-Ab), anti-DKK1 antibody (DKK1-Ab), or Scl-Ab plus DKK1-Ab combination therapy (COMBO) on ulnar osteotomy healing in nonhuman primates (cynomolgus monkeys; 20 to 22 per group). RESULTS: Scl-Ab and COMBO therapy increased systemic markers of bone formation versus VEH, with COMBO leading to synergistic increases versus Scl-Ab or DKK1-Ab monotherapies. The COMBO and Scl-Ab groups showed reduced serum markers of bone resorption versus VEH. The COMBO and DKK1-Ab groups exhibited greater callus bone mineral density (BMD), torsional stiffness, and torsional rigidity versus VEH. Lumbar vertebrae from the Scl-Ab and COMBO groups showed greater BMD and bone formation rate versus VEH, and the femoral mid-diaphysis of the Scl-Ab and COMBO groups showed greater periosteal and endocortical bone formation rates versus VEH. CONCLUSIONS: DKK1-Ab increased BMD and strength at the ulnar osteotomy site, Scl-Ab increased bone formation and BMD at uninjured skeletal sites, and Scl-Ab plus DKK1-Ab combination therapy induced all of these effects, in some cases to a greater degree versus 1 or both monotherapies. These results in nonhuman primates suggest that DKK1 preferentially regulates bone healing while sclerostin preferentially regulates systemic bone mass. CLINICAL RELEVANCE: Combination therapy with antibodies against sclerostin and DKK1 may offer a promising therapeutic strategy for both fracture treatment and fracture prevention.
引用
- Florio M, Kostenuik PJ, Stolina M, et al. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone: An Experimental Study in Nonhuman Primates. J Bone Joint Surg Am. 2023. PMID: 37159527. doi:10.2106/JBJS.22.01092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。